General AML

Results of single agent CC-90009 in R/R AML

L: English
Watch Spanish version

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Jordi Esteve, Hospital Clinic of Barcelona, Barcelona, ES. We asked: Is the administration of single-agent CC-90009, a first-in-class GSPT1 degrader, promising in relapsed/refractory acute myeloid leukemia?

Jordi Esteve discusses the mechanism of action of the single-agent CC-90009, which is a first-in-class GSPT1 degrader. He explains that the compound is promising according to the results of the phase I trial that will be presented during this meeting.